{"id":"https://openalex.org/W2472437016","doi":null,"title":"Tolerability and pharmacokinetics of ebrotidine in healthy subjects given single and repeated oral doses.","display_name":"Tolerability and pharmacokinetics of ebrotidine in healthy subjects given single and repeated oral doses.","publication_year":1997,"publication_date":"1997-04-01","ids":{"openalex":"https://openalex.org/W2472437016","mag":"2472437016","pmid":"https://pubmed.ncbi.nlm.nih.gov/9205758"},"language":"en","primary_location":{"id":"pmid:9205758","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9205758","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arzneimittel-Forschung","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033539160","display_name":"Mag\u0131\u0301 Farr\u00e9","orcid":"https://orcid.org/0000-0001-8338-7543","observed_orcids":["https://orcid.org/0000-0001-8338-7543"]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"M Farr\u00e9","raw_affiliation_strings":["Department of Pharmacology and Toxicology, Institut Municipal d'Investigaci\u00f3 M\u00e8dica, Universitat Aut\u00f2noma de Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology and Toxicology, Institut Municipal d'Investigaci\u00f3 M\u00e8dica, Universitat Aut\u00f2noma de Barcelona, Spain","institution_ids":["https://openalex.org/I123044942"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103588042","display_name":"Pere Nolasc Roset","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P N Roset","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041510647","display_name":"Badenas Jm","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J M Badenas","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019621116","display_name":"Balbina Ugena","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B Ugena","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"M M\u00e1rquez","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M M\u00e1rquez","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084497205","display_name":"Carlos Albet","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C Albet","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033604845","display_name":"E Herrero","orcid":"https://orcid.org/0000-0001-6615-6604","observed_orcids":["https://orcid.org/0000-0001-6615-6604"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E Herrero","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5110619092","display_name":"J A Ortiz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J A Ortiz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.2391,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.53623923,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"47","issue":"4A","first_page":"528","last_page":"30"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.43070000410079956,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.43070000410079956,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.15209999680519104,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11460","display_name":"Analytical Methods in Pharmaceuticals","score":0.11710000038146973,"subfield":{"id":"https://openalex.org/subfields/1602","display_name":"Analytical Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ebrotidine","display_name":"ebrotidine","score":0.9980000257492065},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7139999866485596},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.8960000276565552},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.8109999895095825},{"id":"https://openalex.org/keywords/oral-administration","display_name":"oral administration","score":0.5839999914169312},{"id":"https://openalex.org/keywords/single-dose-administration","display_name":"single-dose administration","score":0.5669999718666077},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8709999918937683},{"id":"https://openalex.org/keywords/elimination-half-life","display_name":"elimination half-life","score":0.9430000185966492},{"id":"https://openalex.org/keywords/plasma-concentration","display_name":"plasma concentration","score":0.7070000171661377},{"id":"https://openalex.org/keywords/h2-receptor-antagonists","display_name":"H2 receptor antagonists","score":0.777999997138977}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.9468562602996826},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8221315741539001},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7008326053619385},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.5903869867324829},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5237417221069336},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.45701247453689575}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001557","descriptor_name":"Benzenesulfonates","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001557","descriptor_name":"Benzenesulfonates","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D001557","descriptor_name":"Benzenesulfonates","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006635","descriptor_name":"Histamine H2 Antagonists","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006635","descriptor_name":"Histamine H2 Antagonists","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D006635","descriptor_name":"Histamine H2 Antagonists","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:9205758","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9205758","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arzneimittel-Forschung","raw_type":"Journal Article"},{"id":"mag:2472437016","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9205758","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9922999739646912}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2418551907","https://openalex.org/W2412712424","https://openalex.org/W2399945437","https://openalex.org/W2417466745","https://openalex.org/W2415434371","https://openalex.org/W2409793110","https://openalex.org/W2074550961","https://openalex.org/W3087516196","https://openalex.org/W1968676466","https://openalex.org/W1998283731"],"abstract_inverted_index":{"The":[0,67],"tolerability":[1],"and":[2,11,51,81,137],"safety":[3],"of":[4,69,128,132,141],"ebrotidine":[5,74,122],"(N-[(E)-[[2-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]":[6],"thio]ethyl]amino]methylene]-4-bromo-benzenesulfonamide,":[7],"CAS":[8],"100981-43-9,":[9],"FI-3542)":[10],"its":[12,19],"basic":[13],"pharmacokinetic":[14],"parameters":[15],"were":[16,27,84,96],"determined":[17],"after":[18,108,126,138],"oral":[20,109,129],"administration":[21,127,140],"to":[22,29,40,48,60,117,134,143],"healthy":[23],"volunteers.":[24],"Sixteen":[25],"subjects":[26],"selected":[28],"participate":[30],"in":[31],"two":[32],"different":[33],"studies:":[34],"an":[35],"increasing":[36],"single":[37,130],"dose":[38,45,54],"study":[39,55,89],"determine":[41],"the":[42,70,88,99],"maximal":[43],"tolerated":[44,125],"(from":[46],"25":[47],"1600":[49,61,135],"mg),":[50],"a":[52,76],"multiple":[53],"(stepped":[56],"doses":[57,131],"from":[58,115],"400":[59],"mg":[62],"daily":[63],"for":[64,147],"12":[65,148],"days).":[66],"results":[68],"studies":[71],"showed":[72],"that":[73],"has":[75],"good":[77],"tolerability.":[78],"Vital":[79],"signs":[80],"laboratory":[82],"tests":[83],"not":[85],"influenced":[86],"by":[87],"treatment.":[90],"No":[91],"clinically":[92],"relevant":[93],"adverse":[94],"effects":[95],"reported":[97],"during":[98],"investigation.":[100],"Ebrotidine":[101],"reached":[102],"peak":[103],"plasma":[104],"concentrations":[105],"2-3":[106],"h":[107,146],"administration.":[110],"Its":[111],"elimination":[112],"half-life":[113],"ranged":[114],"9":[116],"14":[118],"h.":[119],"In":[120],"conclusion,":[121],"was":[123],"well":[124],"up":[133,142],"mg,":[136],"repeated":[139],"800":[144],"mg/12":[145],"days.":[149]},"counts_by_year":[],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2016-07-22T00:00:00"}